Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Waldenstrom Macroglobulinemia 1Recurrence 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoproliferative Disorders 1Hematologic Diseases 1Blood Protein Disorders 1

Interventions

Tacrolimus 4Epoetin Alfa 4Busulfan 4fludarabine 3Darbepoetin alfa 3Bortezomib 3fludarabine phosphate 2dacetuzumab 2Rituximab 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Lenalidomide 2Early Intervention, Educational 2Dexamethasone 2Antilymphocyte Serum 2Alemtuzumab 2venetoclax 1trametinib 1ruxolitinib 1plerixafor 1isatuximab 1ficlatuzumab 1ferrous sulfate 1ferric gluconate 1ethanolamine oleate 1dabrafenib 1Vorinostat 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Tinzaparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × CLR1404 × Plasma cell × Clear all
NCT02952508 2026-03-18

CLOVER-WaM

Cellectar Biosciences, Inc.

Phase 2 Active not recruiting
120 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡